FAS and Hepatic steatosis: While ameliorating hepatic steatosis, cGAMP treatment significantly decreased the mRNA levels of liver acetyl-CoA carboxylase (ACC), an essential lipogenic enzyme, and an insignificant decrease in the mRNA levels of liver fatty acid synthase (FAS), also a lipogenic enzyme.